| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Copper supplement (substance) |
Is a |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Selenium supplement (substance) |
Is a |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron agent |
Is a |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Medicinal product acting as magnesium supplement (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Zinc supplement |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing precisely ferrous fumarate 322 milligram and folic acid 350 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing iron in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing magnesium trisilicate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing iron dextran (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Medicinal product acting as trace element supplement (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing ferrous gluconate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing iron (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Magnesium carbonate mixture BPC |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Aromatic magnesium carbonate mixture BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Compound magnesium trisilicate 250 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Magnesium trisilicate mixture BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Magnesium trisilicate powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Compound magnesium trisilicate oral powder BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Magaldrate 800mg/5mL suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Magnesium carbonate compound tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Magnesium carbonate compound powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Magnesium hydroxide [laxative] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Magnesium sulfate powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Oral iron for iron-deficiency anemias |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing precisely ferrous fumarate 305 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous fumarate 322 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous fumarate 210 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous fumarate 140mg/5mL sugar free syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous fumarate 140mg/5mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous gluconate 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing ferrous glycine sulfate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrocontin Continus 562.5mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous glycine sulfate 562.5mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing ferrous succinate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous sulfate 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous sulfate 60mg/5mL pediatric oral solution BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous sulfate 300mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous sulfate 150mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous sulfate 325mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous sulfate 116mg/mL drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous sulfate 160mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing folic acid and iron (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous sulfate+folic acid 150mg/500micrograms m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous sulfate+folic acid 325mg/350micrograms m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing precisely ferrous fumarate 305 milligram and folic acid 350 microgram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferric ammonium citrate+folic acid 80mg/500micrograms/5mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous sulfate+folic acid 160mg/400micrograms m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferric ammonium citrate+folic acid 80mg/2.5mg/5mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing precisely ascorbic acid 10 milligram and ferrous gluconate 250 milligram and folic acid 5 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Polysaccharide iron complex elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing sodium feredetate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Compound iron preparations |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Parenteral form iron for iron-deficiency anemias |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing iron sorbitol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron sorbitol (50mg/mL Ferrous iron) injection solution 2mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron hydroxide sucrose complex |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron hydroxide sucrose complex 100mg/5mL(Fe) intravenous solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing ferrous phosphate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Sodium ironedetate 190mg/5mL elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Magnesium hydroxide mixture BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous sulfate 30mg/5mL pediatric oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous glycine sulfate syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing ferrous salt |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing precisely magnesium hydroxide 83 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Sodium ferric gluconate complex 12.5mg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron dextran 100mg/2mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron dextran 50mg/mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron sucrose 20mg/mL injection solution 5mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron dextran 50mg/mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Magnesium chloride 200mg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ascorbic acid 60 mg and cyanocobalamin 5 mg and ferrous fumarate 200 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ethinylestradiol 30 microgram and ferrous fumarate 75 mg and norgestrel 300 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous fumarate 324 mg and folic acid 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Folic acid + iron 0.8mg/15mg drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Folic acid + iron 1mg/100mg liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Naphazoline hydrochloride + polyvinyl alcohol + zinc sulfate 0.02%wv/0.25%wv/0.25%wv drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing polysaccharide-iron complex (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron dextran complex 50mg/mL injection solution 2ml ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing magaldrate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing ferrous fumarate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Magnesium-based antacid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing magnesium hydroxide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing zinc sulfate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing magnesium carbonate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing ferrous sulfate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Magnesium trisilicate+belladonna 0.15mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Copper supplement |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Selenium supplement |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing belladonna and magnesium trisilicate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron dextran 50mg/mL injection solution 2mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron dextran 50mg/mL injection solution 1mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron dextran 100mg/2mL injection solution 1mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Iron dextran 100mg/2mL injection solution 2mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Zinc sulfate+epinephrine eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Liquid paraffin+magnesium hydroxide oral emulsion BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous glycine sulfate 562.5mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Ferrous sulfate 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Calcium and magnesium product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Product containing magaldrate and simeticone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
| Infant formula + iron (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Trace element supplementation |
Inferred relationship |
Some |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]